Mauro Marzi
Sigma-Tau
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mauro Marzi.
Journal of Medicinal Chemistry | 2008
Domenico Alloatti; Giuseppe Giannini; Walter Cabri; Isabella Lustrati; Mauro Marzi; Andrea Ciacci; Grazia Gallo; M. Ornella Tinti; Marcella Marcellini; Teresa Riccioni; Mario B. Guglielmi; Paolo Carminati; Claudio Pisano
With the aim of understanding the influence of fluorine on the double bond of the cis-stilbene moiety of combretastatin derivatives and encouraged by a preliminary molecular modeling study showing a different biological environment on the interaction site with tubulin, we prepared, through various synthetic approaches, a small library of compounds in which one or both of the olefinic hydrogens were replaced with fluorine. X-ray analysis on the difluoro-CA-4 analogue demonstrated that the spatial arrangement of the molecule was not modified, compared to its nonfluorinated counterpart. SAR analysis confirmed the importance of the cis-stereochemistry of the stilbene scaffold. Nevertheless, some unpredicted results were observed on a few trans-fluorinated derivatives. The position of a fluorine atom on the double bond may affect the inhibition of tubulin polymerization and cytotoxic activity of these compounds.
Bioorganic & Medicinal Chemistry Letters | 2009
Giuseppe Giannini; Mauro Marzi; Maria Di Marzo; Gianfranco Battistuzzi; Riccardo Pezzi; Tiziana Brunetti; Walter Cabri; Loredana Vesci; Claudio Pisano
In order to gather further knowledge about the structural requirements on histone deacetylase inhibitors (HDACi), starting from the schematic model of the common pharmacophore that characterizes this class of molecules (surface recognition CAP group-connection unit-linker region-Zinc Binding Group), we designed and synthesized a series of hydroxamic acids containing a bis-(indolyl)methane moiety. HDAC inhibition profile and antiproliferative activity were evaluated.
Journal of Medicinal Chemistry | 2001
Fabio Giannessi; Piero Chiodi; Mauro Marzi; Patrizia Minetti; Pompeo Pessotto; Francesco De Angelis; Emanuela Tassoni; Roberto Conti; Fabrizio Giorgi; Massimo Mabilia; Natalina Dell'uomo; Sandra Muck; Maria Ornella Tinti; Paolo Carminati; Arduino Arduini
A series of carnitine related compounds of general formula XCH(2)CHZRCH(2)Y were evaluated as CPT I inhibitors in intact rat liver (L-CPT I) and heart mitochondria (M-CPT I). Derivative 27 (ZR = -HNSO(2)R, R = C(12), X = trimethylammonium, Y = carboxylate, (R) form) showed the highest activity (IC(50) = 0.7 microM) along with a good selectivity (M-CPT I/L-CPTI IC(50) ratio = 4.86). Diabetic db/db mice treated orally with 27 showed a significant reduction of serum glucose levels.
Bioorganic & Medicinal Chemistry Letters | 2009
Giuseppe Giannini; Mauro Marzi; Riccardo Pezzi; Tiziana Brunetti; Gianfranco Battistuzzi; Maria Di Marzo; Walter Cabri; Loredana Vesci; Claudio Pisano
With the aim to discover novel HDAC inhibitors with high potency and good safety profiles, we have designed a small library based on a N-hydroxy-(4-oxime)-cinnamide scaffold. We describe the synthesis of these novel compounds and some preliminary in vitro cytotoxic activity on three tumor cell lines, NB4, H460 and HCT116, as well as their inhibitory activity against class I, II and IV HDAC. Several 4-oxime derivatives demonstrated a promising inhibitory activity on HDAC6 and HDAC8 coupled to a good selectivity profile.
Journal of Medicinal Chemistry | 2012
Roberto Di Santo; Roberta Costi; Giuliana Cuzzucoli Crucitti; Luca Pescatori; Federica Rosi; Luigi Scipione; Diana Celona; Mario Vertechy; Orlando Ghirardi; Paola Piovesan; Mauro Marzi; Silvio Caccia; Giovanna Guiso; Fabrizio Giorgi; Patrizia Minetti
Dyes like CR are able to inhibit the aggregation of Aβ fibrils. Thus, a screening of a series of dyes including ABBB (1) was performed. Its main component 2 tested in an in vitro assay (i.e., ThT assay) showed good potency at inhibiting fibrils association. Congeners 4-9 have been designed and synthesized as inhibitors of Aβ aggregation. A number of these newly synthesized compounds have been found to be active in the ThT assay with IC(50) of 1-57.4 μM. The most potent compound of this series, 4k, showed micromolar activity in this test. Another potent derivative 4q (IC(50) = 5.6 μM) rapidly crossed the blood-brain barrier, achieving whole brain concentrations higher than in plasma. So 4q could be developed to find novel potent antiaggregating βA agents useful in Alzheimer disease as well as other neurological diseases characterized by deposits of amyloid aggregates.
Bioorganic & Medicinal Chemistry Letters | 2008
Giuseppe Giannini; Mauro Marzi; Walter Cabri; Elena Marastoni; Gianfranco Battistuzzi; Loredana Vesci; Claudio Pisano; Giovanni Luca Beretta; Michelandrea De Cesare; Franco Zunino
In contrast to five-membered E-ring analogues, 7-oxyiminomethyl derivatives of homocamptothecins showed ability to form stable ternary complexes with DNA and topoisomerase I. The 7-oxyiminomethyl derivatives of homocamptothecins were evaluated as a racemic mixture. Following the isolation of the two enantiomers, the 20 (R)-hydroxy isomer confirms the best activity. By using a panel of human tumor cells, all tested homocamptothecins showed a potent antiproliferative activity, correlating to the persistence of the cleavable complex. No significant difference was observed between the natural scaffold and the corresponding homocamptothecin homologue. A selected compound of this series exhibited an excellent antitumor activity against human gastrointestinal tumor xenografts.
Tetrahedron | 1992
Mauro Marzi; Patrizia Minetti; D. Misiti
Abstract Pyrrolidines 1 and 2 are obtained from D-Mannitol, giving good total yields and in an enantiomerically pure form. Some comments and studies regarding pyrrolidine ring closure (key step) are also reported.
European Journal of Medicinal Chemistry | 2014
Gilberto Spadoni; Annalida Bedini; Silvia Bartolucci; Daniele Pala; Marco Mor; Teresa Riccioni; Franco Borsini; Walter Cabri; Diana Celona; Mauro Marzi; Giorgio Tarzia; Silvia Rivara; Patrizia Minetti
Many known 5-HT7 ligands contain either a serotonin-like or an arylpiperazine structure that, in published SAR studies, are generally supposed to bind the same receptor pocket. Conversely, we explored the hypothesis that two such moieties can co-exist in the same ligand, binding to different pockets. We thus designed and synthesized a set of compounds including both a 5-hydroxyindol-3-ylethyl and a 1-arylpiperazine moieties connected by a short linker. The compounds were tested for their affinity for human 5-HT7 serotonin receptor. We further prepared a novel series of 5-HT7 ligands, where the 5-hydroxyindol-3-ylethyl moiety was bioisosterically replaced by a 3-hydroxyanilinoalkyl one. Among the newly synthesized compounds, potent ligands at the 5-HT7 receptor, behaving as antagonists in functional tests, were identified, even if they showed limited subtype selectivity. Docking studies within a model of the 5-HT7 receptor showed that the binding site can actually accommodate both moieties, with the serotonin-like one in the putative orthosteric site and the arylpiperazine one occupying an accessory pocket. The present results demonstrate that it is possible to devise and develop new 5-HT7 ligands merging two privileged structures in the same molecule.
Journal of Medicinal Chemistry | 2001
Sabrina Dallavalle; Anna Maria Ferrari; Barbara Biasotti; Lucio Merlini; Sergio Penco; Grazia Gallo; Mauro Marzi; Maria Ornella Tinti; Roberta Martinelli; Claudio Pisano; Paolo Carminati; Nives Carenini; Giovanni Luca Beretta; Paola Perego; Michelandrea De Cesare; Graziella Pratesi; Franco Zunino
Archive | 1999
Fabio Giannessi; Mauro Marzi; Patrizia Minetti; Francesco De Angelis; Maria Ornella Tinti; Piero Chiodi; Arduino Arduini